No immediate trading implication; monitor for future Form 4 filings that may indicate actual transactions. The disclosure reflects passive ownership through Illumina funds and does not signal active involvement or sentiment from Naclerio.
Price Chart
Executive Summary
Nicholas Naclerio, a director of Alamar Biosciences (ALMR), filed a Form 3 to report beneficial ownership of securities held by Illumina Innovation Fund II and III, for which he serves as managing member of the general partners. The filing is a routine initial disclosure of indirect holdings in connection with board membership and includes a power of attorney for filing future Section 16 reports.
Key Facts
- Nicholas Naclerio is a member of Alamar Biosciences' board of directors.
- He filed a Form 3 to disclose indirect beneficial ownership of preferred stock and convertible notes held by Illumina Innovation Fund II and III.
- The securities include Series A-3, A-4, B, and C Preferred Stock convertible into Class B Common Stock, and convertible promissory notes that will convert into common stock upon IPO.
- Naclerio disclaims beneficial ownership except to the extent of his pecuniary interest.
- A power of attorney was granted to four company executives to file future Section 16 reports on his behalf.
Financial Impact
No direct financial impact disclosed; holdings are indirect and held by affiliated funds.
Risk Factors
- Potential perception of increased Illumina influence over Alamar due to board representation and fund ownership.
- Future conversion of preferred stock and notes upon IPO could lead to dilution, though terms are standard for private-stage financing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001534166-26-000004 |
| Document: 0001534166-26-000004-index-headers.html | 0001534166-26-000004 |
| Document: 0001534166-26-000004-index.html | 0001534166-26-000004 |
| Document: 0001534166-26-000004.txt | 0001534166-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (−10.83%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (−10.83%) |
Oct 14, 2026 12d ago | 144 | $27.42 | awaiting T+60 | — | $30.39 (+10.83%) |
Oct 5, 2026 21d ago | Press Release | $32.26 | awaiting T+60 | — | $30.39 (−5.80%) |
Sep 24, 2026 4w ago | Press Release | $32.80 | awaiting T+60 | — | $30.39 (−7.35%) |
Sep 1, 2026 7w ago | 8-K | $30.49 | awaiting T+60 | — | $30.39 (−0.33%) |
Aug 10, 2026 11w ago | 8-K | $36.57 | awaiting T+60 | — | $30.39 (−16.90%) |
Jul 13, 2026 15w ago | Press Release | $27.40 $32.26 | ▲ +17.74% | ▲ +13.74% | $30.39 (+10.91%) |
Jul 10, 2026 15w ago | Press Release | $28.42 $38.13 | ▲ +34.17% | ▲ +31.53% | $30.39 (+6.93%) |
May 8, 2026 24w ago | 8-K | $23.96 $27.11 | ▲ +13.15% | ▲ +8.31% | $30.39 (+26.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers